Chronic obstructive pulmonary disease(COPD)has garnered increased attention as a result of its persistent symptoms,which undermine patientsʼquality of life.Fudosteine has substantial advantages in the treatment of COP...Chronic obstructive pulmonary disease(COPD)has garnered increased attention as a result of its persistent symptoms,which undermine patientsʼquality of life.Fudosteine has substantial advantages in the treatment of COPD due to its high efficacy and low adverse effects.In this study,Fudosteine sulfonamide derivatives Series I and amine derivatives Series II were designed and synthesized,and their biological activities were evaluated.The results showed that compound 6f had outstanding anti-inflammatory action with an IC_(50) of 1.08 mmol/L,and a higher antioxidant capacity than the lead molecule.At the same time,molecular docking investigations have revealed that compound 6f establishes hydrogen bonds and hydrophobic contacts with the MUC5AC protein.Furthermore,derivative 1f inhibited PDE4A1 enzyme activity five times more than Fudosteine.2,2-Diphenyl-1-picrylhydrazyl(DPPH)free radical scavenging tests demonstrated that all examined substances had higher antioxidant activity than Fudosteine.This study established a solid foundation for further research into COPD drug therapy.展开更多
文摘Chronic obstructive pulmonary disease(COPD)has garnered increased attention as a result of its persistent symptoms,which undermine patientsʼquality of life.Fudosteine has substantial advantages in the treatment of COPD due to its high efficacy and low adverse effects.In this study,Fudosteine sulfonamide derivatives Series I and amine derivatives Series II were designed and synthesized,and their biological activities were evaluated.The results showed that compound 6f had outstanding anti-inflammatory action with an IC_(50) of 1.08 mmol/L,and a higher antioxidant capacity than the lead molecule.At the same time,molecular docking investigations have revealed that compound 6f establishes hydrogen bonds and hydrophobic contacts with the MUC5AC protein.Furthermore,derivative 1f inhibited PDE4A1 enzyme activity five times more than Fudosteine.2,2-Diphenyl-1-picrylhydrazyl(DPPH)free radical scavenging tests demonstrated that all examined substances had higher antioxidant activity than Fudosteine.This study established a solid foundation for further research into COPD drug therapy.